CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-30 | Reeve Emma Director | Option exercise 10b5-1 | +12,000 | $38.10 | $457K | 18,666 |
| 2025-10-30 | Reeve Emma Director | Sale 10b5-1 | −12,000 | $69.50 | $834K | 6,666 |
| 2025-10-30 | Reeve Emma Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 0 | ||
| 2025-10-07 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +3,375 | $38.10 | $129K | 107,276 |
| 2025-10-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,757 | $62.89 | $110K | 105,519 |
| 2025-10-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,306 | $63.80 | $83K | 104,213 |
| 2025-10-07 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −312 | $64.97 | $20K | 103,901 |
| 2025-10-07 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,375 | 3,376 | ||
| 2025-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,266 | $39.42 | $89K | 106,167 |
| 2025-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −2,266 | $65.07 | $147K | 103,901 |
| 2025-10-06 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,266 | 11,329 | ||
| 2025-10-03 | Reeve Emma Director | Option exercise 10b5-1 | +10,000 | $39.42 | $394K | 20,332 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −3,028 | $65.09 | $197K | 17,304 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −4,591 | $66.09 | $303K | 12,713 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −2,381 | $66.87 | $159K | 10,332 |
| 2025-10-03 | Reeve Emma Director | Option exercise 10b5-1 | +6,912 | $33.02 | $228K | 17,244 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −2,163 | $65.02 | $141K | 15,081 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −3,149 | $66.11 | $208K | 11,932 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −1,600 | $66.93 | $107K | 10,332 |
| 2025-10-03 | Reeve Emma Director | Option exercise 10b5-1 | +8,650 | $33.63 | $291K | 18,982 |
Page 20 of 25 · 493 trades